With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to establish its own salesforce to market Treakisym (and other drugs) in Japan. While the company has not yet made a final decision, we think it is highly likely to move to self-commercialization in order to improve operating margins after its marketing arrangement with Eisai expires. Therefore, we now model self-commercialization in our base-case valuation
09 Apr 2018
SymBio Pharmaceuticals - Self-commercialization gains favor
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - Self-commercialization gains favor
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
09 Apr 2018 -
Author:
Dr Dennis Hulme -
Pages:
14
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to establish its own salesforce to market Treakisym (and other drugs) in Japan. While the company has not yet made a final decision, we think it is highly likely to move to self-commercialization in order to improve operating margins after its marketing arrangement with Eisai expires. Therefore, we now model self-commercialization in our base-case valuation